March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) h..
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,
Welcome to CancerFax !
CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.
Let us know what we can do for you.
1) Cancer treatment abroad? 2) CAR T-Cell therapy 3) Cancer vaccine 4) Online video consultation 5) Proton therapy